In this article, we are going to take a look at where Geron Corporation (NASDAQ:GERN) stands against other best stocks to penny stocks that will skyrocket. Is It a Good Time to Diversify Your ...
H.C. Wainwright downgraded Geron (GERN) to Neutral from Buy without a price target following the Q4 report. The shift in guidance for interim data from the IMpactMF study to the second half of ...
Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase inhibitor, which we believe represents a highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback